NDAORALTABLETPriority Review
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Mechanism of Action
α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these…
Clinical Trials (5)
Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation
Started Aug 2016
152 enrolled
Nicotine Dependence
Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)
Started Feb 2012
7 enrolled
Breast CancerTobacco Dependence
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Started Oct 2009
20 enrolled
Spinocerebellar Ataxia Type 3
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
Started May 2009
28 enrolled
Friedreich's Ataxia
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
Started Mar 2009
0Schizophrenia